CONCORD Stock View

Concord Drugs Ltd
stock-view-header

icon 0.60 | 1.76
Market Cap ₹( Cr.)
346.80
Proj. P/E (x)
Proj. P/BV (x)
Proj. ROE (%)
Proj EV / EBITDA (x)
--
Proj. Revenue ( Cr.)

Stock View

Last Updated On.
26-Nov-2023
 

The average score for Concord Drugs Ltd stands at 3 against 5, three months back.

Concord Drugs Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing of licensed drugs based on the formulations approved. The Company offers finished pharmaceutical formulations, such as injectables (small volume parenteral, dry powders), tissue bio-adhesive, tablets, capsules, liquid orals (syrup & suspension) and dry syrups (powder). The Company also provides ready-to-fill pellets and multiple unit pellets system (MUPS). Its pellets are categorized as gastrointestinal drug pellets, cardiovascular drug pellets, respiratory drug pellets, anti-obesity drug pellets, anti-depressant drug pellets, central nervous system drug pellets, urological drug pellets, anti-microbial, anti-infective and adjuvant drugs pellets, taste mask drug pellets/powder, nutrition and food supplement drug pellets, anti-cholesterol drug pellets. The Company also provides Iso Amyl 2-Cyano Acrylate, which is a bio-adhesive product.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.


Technical Data

50 DMA(₹)
34.08
100 DMA(₹)
33.54
200 DMA(₹)
31.05
52 Weeks Range
24.80     41.80

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required